SIGNIFICANT ACCOUNTING POLICIES (Details) $ / shares in Units, $ in Thousands					1 Months Ended	3 Months Ended		9 Months Ended
	Aug. 29, 2022	May 13, 2021 USD ($)	Jul. 23, 2018 USD ($)	Oct. 19, 2017 USD ($)	Oct. 31, 2015	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($) shares	Sep. 30, 2024 USD ($) agreement $ / shares	Sep. 30, 2023 USD ($)	Dec. 31, 2023 $ / shares	Feb. 27, 2023 USD ($)	Jul. 02, 2021 USD ($) $ / shares
SIGNIFICANT ACCOUNTING POLICIES
Number of global licensing and supply agreements | agreement								2
Common Stock, Par or Stated Value Per Share | $ / shares								$ 0.001		$ 0.001
Stock issuance proceeds									$ 23,954
ATM Shares
SIGNIFICANT ACCOUNTING POLICIES
Number of shares issued (in shares) | shares							13,980,060
Common Stock, Par or Stated Value Per Share | $ / shares												$ 0.001
Sale of stock, maximum offering price								$ 6,400			$ 20,000	$ 20,000
Stock issuance proceeds							$ 20,000
2024 Notes
SIGNIFICANT ACCOUNTING POLICIES
Interest rate (as a percent)								7.50%
Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil
SIGNIFICANT ACCOUNTING POLICIES
Collaborative arrangement revenues and expenses sharing percentage					100.00%
Chiesi Agreements
SIGNIFICANT ACCOUNTING POLICIES
Amount of milestone payment received						$ 20,000		$ 20,000
Chiesi US Agreement
SIGNIFICANT ACCOUNTING POLICIES
Additional amounts payable to cover development costs			$ 20,000
Additional amount payable for achievement of regulatory and commercial milestones			$ 760,000
Chiesi US Agreement | Minimum
SIGNIFICANT ACCOUNTING POLICIES
Payment on net sales percentage			15.00%
Chiesi US Agreement | Maximum
SIGNIFICANT ACCOUNTING POLICIES
Payment on net sales percentage			40.00%
Chiesi Ex-US Agreement
SIGNIFICANT ACCOUNTING POLICIES
Additional amounts payable to cover development costs				$ 25,000
Agreement amendment payment receivable		$ 10,000
Change in amount receivable for achievement of regulatory and commercial milestones		$ 25,000
Additional amount payable for achievement of regulatory and commercial milestones				$ 320,000
Chiesi Ex-US Agreement | Minimum
SIGNIFICANT ACCOUNTING POLICIES
Payment on net sales percentage				15.00%
Chiesi Ex-US Agreement | Maximum
SIGNIFICANT ACCOUNTING POLICIES
Payment on net sales percentage				35.00%
Chiesi US Agreement and Chiesi Ex-US Agreement
SIGNIFICANT ACCOUNTING POLICIES
Non-refundable payment receivable			$ 25,000	$ 25,000
Fill/Finish Agreement
SIGNIFICANT ACCOUNTING POLICIES
Extended term of agreement	7 years